Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of intranasal live attenuated influenza vaccine in healthy people aged 3 to 59 years
CTR20220581Phase 2Completed
- Sponsor
- Changchun Baimu Biotechnology
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of quadrivalent live attenuated influenza vaccine in influenza, sponsored by Changchun Baimu Biotechnology. Started Mar 2022; status: completed.
02
Drugs
quadrivalent live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20220581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220581.